Cancer Res Treat.  2003 Apr;35(2):123-129.

Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer

• Kim YT
• Sohn JH
• Kim SH
• Rha SY
• Kim C
• Roh JK
• Kim BS
• Jang WI
• Chung HC

Abstract

PURPOSE
This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma. MATERIALS AND METHODS: Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1, 000 mg/m2 intravenous (IV) 24 hour infusion (Day 1~3), leucovorin 20 mg/m2 (Day 1~3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks. RESULTS: The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range: 4~24), the median time to response was 8 weeks (range: 8~20) the median time to progression was 30.0 weeks (95% CI: 16.3~43.2) and the median overall survival duration was 36.0 weeks (95% CI: 1.7~70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity. CONCLUSION: This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients.

Keyword

Stomach neoplasm; Combination Chemotherapy; Infusional 5-FU; Leucovorin; Docetaxel

MeSH Terms

Anemia
Diarrhea
Drug Therapy
Drug Therapy, Combination
Fluorouracil*
Humans
Leucovorin*
Mucositis
Nausea
Neutropenia
Stomach Neoplasms*
Vomiting
Fluorouracil
Leucovorin